Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
129.11
-0.29 (-0.22%)
Jul 3, 2025, 1:00 PM - Market closed
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $572.60M in the quarter ending March 31, 2025, with 11.12% growth. This brings the company's revenue in the last twelve months to $2.41B, up 21.73% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm)
$2.41B
Revenue Growth
+21.73%
P/S Ratio
5.37
Revenue / Employee
$1,340,333
Employees
1,800
Market Cap
12.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NBIX News
- 3 days ago - Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist - PRNewsWire
- 6 days ago - Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PRNewsWire
- 13 days ago - Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia - PRNewsWire
- 24 days ago - Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - PRNewsWire
- 4 weeks ago - Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewsWire
- 4 weeks ago - Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia - PRNewsWire
- 5 weeks ago - Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewsWire
- 5 weeks ago - Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - PRNewsWire